Chinese stem cell therapy reverses heart failure in 90% of patients in landmark trial
Nanjing Drum Tower Hospital in east China has reported significant success in a phase 2 clinical study using reprogrammed stem cells to treat severe heart failure. Published in Nature Medicine, the study found that 90% of patients injected with heart muscle cells derived from induced pluripotent stem cells (iPSCs) showed substantially improved cardiac function after 12 months compared to a control group.

Briefing Summary
AI-generatedNanjing Drum Tower Hospital in east China has reported significant success in a phase 2 clinical study using reprogrammed stem cells to treat severe heart failure. Published in Nature Medicine, the study found that 90% of patients injected with heart muscle cells derived from induced pluripotent stem cells (iPSCs) showed substantially improved cardiac function after 12 months compared to a control group. This novel therapy helps ageing or damaged hearts grow new muscle tissue, a critical development as dead heart muscle cannot regrow. The research addresses the limitations of heart transplants due to donor scarcity for patients suffering from debilitating symptoms of severe heart failure.
Article analysis
Model · rule-basedKey claims
4 extractedNine out of 10 heart failure patients injected with iPSCs had significantly better cardiac function at 12-month follow-up.
90% of patients showed significant recovery in heart function after the novel therapy.
Chinese hospital used reprogrammed stem cells to treat severe heart failure.
Stem cell technology can help ageing or damaged hearts grow new muscle tissue and restore function.